SINOPHARM GROUP 1/5/O.N. (X2S1) - Total Liabilities

Latest as of December 2025: €256.20 Billion EUR ≈ $299.53 Billion USD

Based on the latest financial reports, SINOPHARM GROUP 1/5/O.N. (X2S1) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check X2S1 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

SINOPHARM GROUP 1/5/O.N. - Total Liabilities Trend (2021–2025)

This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SINOPHARM GROUP 1/5/O.N. (X2S1) total assets.

SINOPHARM GROUP 1/5/O.N. Competitors by Total Liabilities

The table below lists competitors of SINOPHARM GROUP 1/5/O.N. ranked by their total liabilities.

Company	Country	Total Liabilities
Koninklijke BAM Groep NV AS:BAMNB	Netherlands	€2.96 Billion
MAG Silver Corp TO:MAG	Canada	CA$23.47 Million
Ratch Group Public Company Limited BK:RATCH	Thailand	฿130.36 Billion
Jilin Power Share Co Ltd SHE:000875	China	CN¥60.72 Billion
Adani Wilmar Limited NSE:AWL	India	Rs-104.44 Billion
Shenzhen Colibri Technologies Co Ltd SHE:002957	China	CN¥2.92 Billion
WD-40 Company NASDAQ:WDFC	USA	$195.60 Million
Chung-Hsin Electric & Machinery Mfg Corp TW:1513	Taiwan	NT$26.88 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down SINOPHARM GROUP 1/5/O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SINOPHARM GROUP 1/5/O.N. (X2S1) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.66	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SINOPHARM GROUP 1/5/O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SINOPHARM GROUP 1/5/O.N. (2021–2025)

The table below shows the annual total liabilities of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€256.20 Billion ≈ $299.53 Billion	-3.74%
2024-12-31	€266.14 Billion ≈ $311.15 Billion	+1.17%
2023-12-31	€263.08 Billion ≈ $307.56 Billion	+3.29%
2022-12-31	€254.71 Billion ≈ $297.78 Billion	+8.04%
2021-12-31	€235.76 Billion ≈ $275.63 Billion	--

About SINOPHARM GROUP 1/5/O.N.

F:X2S1 Germany Medical Distribution

Market Cap

$2.57 Billion

€2.20 Billion EUR

Market Cap Rank

#5379 Global

#857 in Germany

Share Price

€8.20

Change (1 day)

+1.86%

52-Week Range

€8.05 - €11.80

All Time High

€14.56